Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: Results from the STAR 3 randomized trial

Medical Decision Making

Volumn 33, Issue 2, 2013, Pages 215-224

  Kamble, Shital ^a,b   Weinfurt, Kevin P ^a   Schulman, Kevin A ^a   Reed, Shelby D ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IQVIA   (United States)

Author keywords

clinical research methodology; cohort studies; decision aids tools; judgment and decision psychology; physician patient communication; shared decision making

Indexed keywords

INSULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECONOMICS; HEALTH CARE COST; HUMAN; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TASK PERFORMANCE;

ADOLESCENT; ADULT; AGED; CHILD; DIABETES MELLITUS, TYPE 1; HEALTH CARE COSTS; HUMANS; INFUSION PUMPS; INSULIN; MIDDLE AGED; TIME AND MOTION STUDIES; YOUNG ADULT;

EID: 84874496255     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X12464824     Document Type: Article

References (36)

1. Department of Health and Human Services, Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed 18 August 2011.
2. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 ; 329 (14). 977-86
3. Standards of medical care in diabetes - 2011. Diabetes Care. 2011 ; 34: S11-61
4. JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther. 2008 ; 10 (4). 310-21
5. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010 ; 363 (4). 311-20
6. Gold MR, Siegel JE, Russell LB, WeinsteinMC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
7. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276 (15). 1253-8 (Pubitemid 26337709)
8. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276 (16). 1339-41 (Pubitemid 26346934)
9. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 ; 276 (14). 1172-7 (Pubitemid 26329746)
10. Jonas DE, Russell LB, Sandler RS, Chou J, Pignone M. Value of patient time invested in the colonoscopy screening process: time requirements for colonoscopy study. Med Decis Making. 2008 ; 28 (1). 56-65
11. Jonas DE, Russell LB, Sandler RS, Chou J, Pignone M. Patient time requirements for screening colonoscopy. Am J Gastroenterol. 2007 ; 102 (11). 2401-10 (Pubitemid 47631758)
12. Jonas DE, Bryant Shilliday B, Laundon WR, Pignone M. Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making. 2010 ; 30 (2). 206-16
13. Huang ES, O'Grady M, Basu A, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2010 ; 33 (6). 1269-74
14. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Diabetes Technol Ther. 2010 ; 12 (4). 249-55
15. Gold M. Panel on Cost-Effectiveness in Health and Medicine. Med Care. 1996 ; 34 (12). DS197-9
16. US Department of Labor, Bureau of Labor Statistics. Employer costs for employee compensation - March 2010. Available from: http://www.bls.gov/news. release/archives/ecec-06092010.pdf. Accessed 17 June 2011.
17. SAS version 9.2. Cary, NC: SAS Institute, Inc; 2004.
18. Russell LB, Suh DC, Safford MA. Time requirements for diabetes self-management: too much for many?. J Fam Pract. 2005 ; 54 (1). 52-6 (Pubitemid 40105222)
19. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007 ; 7: 30
20. Franke RH, Kaul JD. Hawthorne experiments - 1st statistical interpretation. Am Sociol Rev. 1978 ; 43 (5). 623-43
21. Russell LB. Completing costs: patients' time. Med Care. 2009 ; 47 (7). S89-93
22. Scuffham P, Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabetes Med. 2003 ; 20 (7). 586-93 (Pubitemid 36886475)
23. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabetes Med. 2005 ; 22 (9). 1239-45 (Pubitemid 41224186)
24. Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics. 2007 ; 25 (10). 881-97
25. St Charles M, Lynch P, Graham C, Minshall ME. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. Value Health. 2009 ; 12 (5). 674-86
26. St Charles ME, Sadri H, Minshall ME, Tunis SL. Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. Clin Ther. 2009 ; 31 (3). 657-67
27. Cummins E, Royle P, Snaith A, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess. 2010 ; 14 (11). iii xi 1 - iv xvi 181
28. Russell LB, Safford MM. The importance of recognizing patients' time as a cost of self-management. Am J Manag Care. 2008 ; 14 (6). 131-40
29. Juster FT, Stafford FP. The allocation of time: empirical-findings, behavioral-models, and problems of measurement. J Econ Lit. 1991 ; 29 (2). 471-522
30. Safford MM, Russell L, Suh DC, Roman S, Pogach L. How much time do patients with diabetes spend on self-care?. J Am Board Fam Pract. 2005 ; 18 (4). 262-70 (Pubitemid 41663997)
31. Ettner SL, Cadwell BL, Russell LB, et al. Investing time in health: do socioeconomically disadvantaged patients spend more or less extra time on diabetes self-care?. Health Econ. 2009 ; 18 (6). 645-63
32. Cantor SB, Levy LB, Cardenas-Turanzas M, et al. Collecting direct non-health care and time cost data: application to screening and diagnosis of cervical cancer. Med Decis Making. 2006 ; 26 (3). 265-72 (Pubitemid 43726012)
33. Robbins JM, Tilford JM, Gillaspy SR, et al. Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis. Ambul Pediatr. 2002 ; 2 (6). 444-8
34. Yabroff KR, Warren JL, Knopf K, Davis WW, Brown ML. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005 ; 43 (7). 640-8 (Pubitemid 40993758)
35. Whitney CW, Milgrom P, Conrad D, Fiset L, OHara D. The relationship between price of services, quality of care, and patient time costs for general dental practice. Health Serv Res. 1997 ; 31 (6). 773-90 (Pubitemid 27053533)
36. Tranmer JE, Guerriere DN, Ungar WJ, Coyte PC. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics. 2005 ; 23 (5). 449-59 (Pubitemid 40994134)